Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Steurer

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Translational Research : the Journal of Laboratory and Clinical Medicine|March 6, 2017
Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemiaAndrea Piccin, Michael Steurer, Clemens Feistritzer, et al.
Plos One|October 23, 2013
Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2Thorsten Klampfl, Jelena D Milosevic, Ana Puda, et al.
Blood|March 5, 2016
BRAF inhibition in hairy cell leukemia with low-dose vemurafenibSascha Dietrich, Andreas Pircher, Volker Endris, et al.
Internal and Emergency Medicine|January 15, 2015
Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemiaAndrea Piccin, Michael Steurer, Manfred Mitterer, et al.
Leukemia|February 24, 2018
Chromothripsis in acute myeloid leukemia: biological features and impact on survivalMaria Chiara Fontana, Giovanni Marconi, Jelena D Milosevic Feenstra, et al.
American Journal of Hematology|August 14, 2012
Clinical significance of genetic aberrations in secondary acute myeloid leukemiaJelena D Milosevic, Ana Puda, Luca Malcovati, et al.
The Lancet. Haematology|July 5, 2016
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trialRichard Greil, Petra Obrtlíková, Lukáš Smolej, et al.
Cancer Medicine|March 20, 2019
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trialAlexander Egle, Thomas Melchardt, Petra Obrtlíková, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Translational Research : the Journal of Laboratory and Clinical Medicine|March 6, 2017
Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemiaAndrea Piccin, Michael Steurer, Clemens Feistritzer, et al.
Plos One|October 23, 2013
Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2Thorsten Klampfl, Jelena D Milosevic, Ana Puda, et al.
Blood|March 5, 2016
BRAF inhibition in hairy cell leukemia with low-dose vemurafenibSascha Dietrich, Andreas Pircher, Volker Endris, et al.
Internal and Emergency Medicine|January 15, 2015
Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemiaAndrea Piccin, Michael Steurer, Manfred Mitterer, et al.
Leukemia|February 24, 2018
Chromothripsis in acute myeloid leukemia: biological features and impact on survivalMaria Chiara Fontana, Giovanni Marconi, Jelena D Milosevic Feenstra, et al.
American Journal of Hematology|August 14, 2012
Clinical significance of genetic aberrations in secondary acute myeloid leukemiaJelena D Milosevic, Ana Puda, Luca Malcovati, et al.
The Lancet. Haematology|July 5, 2016
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trialRichard Greil, Petra Obrtlíková, Lukáš Smolej, et al.
Cancer Medicine|March 20, 2019
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trialAlexander Egle, Thomas Melchardt, Petra Obrtlíková, et al.
Pageof 8